Jasper Therapeutics Inc. has reported its financial results for the second quarter of 2025. The company, focused on developing briquilimab for mast cell-driven diseases, announced a net loss of $26.7 million for the three months ending June 30, 2025. This translates to a net loss per share attributable to common stockholders of $1.74. The research and development expenses for this period were $21.2 million, while general and administrative expenses amounted to $5.9 million. Jasper's cash and cash equivalents totaled $39.5 million as of June 30, 2025. In a significant operational update, Jasper has decided to halt its non-mast cell focused clinical and preclinical programs, including the SCID clinical program, to concentrate fully on the development of briquilimab. Enrollment in the ETESIAN study in asthma has been paused, with further data and decisions expected after the investigation into specific BEACON study cohorts concludes in the latter half of 2025. The company also plans to redose patients and enroll additional participants in the BEACON study cohorts and aims to report related data by late 2025.